Quantum Genomics Corp (QGC) has announced that it has appointed Lionel Segard as Chief Executive Officer.
QGC's business is identifying and developing human health discovery projects in areas where there is a significant unmet medical need.
The company intends to zero in on the many high-potential academic discoveries that never make it beyond the academic research laboratory, and provide the know-how that academics require to bring their discoveries to market.
QGC has already earmarked EUR 3 million to finance early stage projects. This will enable QGC to begin the identification and selection of research projects in Europe, as well as to recruit a range of specialists to provide the required management, scientific and other expertise.
"Lionel Ségard is a leading expert in sourcing, developing, and financing innovative biotechnology projects," said Jonathan McCann, board member of QGC.
"Lionel's experience in building teams of experts from a variety of backgrounds is a tremendous asset to QGC."
"QGC is a new type of company that has a huge growth potential," said Lionel Segard.
"I am proud to apply my experience for the benefit of the company and to bring products to market that would not otherwise exist."
"We expect to develop new treatments not only for common diseases but also for orphan diseases."
"We are already examining a number of projects and plan to start development of these projects before year-end."
A qualified biochemist, Lionel Segard, 38, was CEO of Inserm-Transfert, Inserm's technology transfer arm, until March 2006.
He is also a founder member of France's Strategic Council for Innovation where he was secretary general from 2003-2005.
The Council's goal is to boost French efforts in the field of research and advanced technologies and includes key individuals from France's science, industry and financial community.